Sep 3, 2009 - Bristol-Myers Squibb Company announced today that the U.S. FDA has accepted, for filing and review, the company's submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation.
The details can be read here.
No comments:
Post a Comment